InflaRx Facing Nasdaq Delisting Risk Over Stock Price
Event summary
- InflaRx received a Nasdaq deficiency notice on March 11, 2026, for its stock price falling below the $1 minimum bid requirement for 30 consecutive days.
- The company has until September 7, 2026, to regain compliance or risk delisting.
- If non-compliant, InflaRx may apply to transfer to the Nasdaq Capital Market, extending the deadline to March 8, 2027.
- The notice does not immediately affect trading of InflaRx’s shares.
The big picture
InflaRx’s stock price deficiency highlights the broader challenge biopharmaceutical companies face in maintaining market compliance amid volatile investor sentiment. The company’s focus on anti-inflammatory therapeutics, particularly its lead program izicopan, may influence its ability to regain investor confidence and stabilize its stock price. The situation underscores the importance of financial performance in sustaining market listings, especially for firms operating in competitive healthcare sectors.
What we're watching
- Market Recovery
- Whether InflaRx can stabilize its stock price above $1 within the 180-day compliance period.
- Regulatory Compliance
- The likelihood of Nasdaq granting an extension if InflaRx fails to meet the minimum bid price.
- Strategic Options
- How InflaRx plans to address the deficiency notice, including potential transfer to the Nasdaq Capital Market.
Related topics